A phase I pharmacokinetic, pharmacogenomic trial of weekly amonafide in patients (pts) with solid tumors.


2023 Background: Amonafide (AMF) is a topoisomerase II inhibitor previously tested in clinical trials, predominantly with a daily x 5 administration schedule. AMF is extensively metabolized by N-acetyltransferase 2 to N-acetylamonafide (AAMF), an active metabolite which demonstrates nearly equipotent activity to the parent compound. Previous trials… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.